International Childhood Cancer Data Partnership

Archives du blog

Tamara MILLER

Tamara MILLER

Tamara MILLER

USA - Emory University School of Medicine

Pr. Tamara Miller is an Associate Professor in the Department of Pediatrics, Division of Hematology/Oncology at Emory University and pediatric oncologist at Children’s Healthcare of Atlanta.

Her research is focused on improving knowledge of adverse events and outcomes experienced by children during treatment for cancer and performing clinical epidemiology research in supportive care that will improve daily clinical care. Her research aims to develop a novel approach that leverages electronic health record (EHR) data to describe cancer treatments, toxicities, and outcomes.

Using ExtractEHR, the R package that we have developed, they can provide detailed data for cohorts such as registries that can be used to answer clinical research questions. The results of her research will provide clinicians and researchers with a more accurate and detailed understanding of patient experience during chemotherapy that can be used to guide clinical decisions and provide the foundation for future trials.

November 8 – 10 – 11.15am

Session: Workshop #4 Innovative Models &  Data Management – Session 3 

Role: Discussant

See others scientific committee members :

Véronique MINARD-COLIN

Véronique MINARD-COLIN

Véronique MINARD-COLIN

France - Société Française Cancer Enfant (SFCE)

Véronique Minard-Colin is professor of Pediatrics at Paris Saclay University.​

Specialist in pediatric lymphomas and sarcomas, and in the immunology of childhood cancers, she is head of the Immunotherapy program at Gustave Roussy’s Department of Child and Adolescent Oncology, which uses innovative approaches to better understand the mechanisms of immune evasion in childhood cancers to develop effective immunotherapies.​

She was elected vice-president of the ‘Société Française des Cancers de l’Enfant’ (SFCE) in 2019 and is a member of several European boards and groups, including the European childhood non-Hodgkin’s lymphoma (EICNHL) and the European Paediatric Sarcoma Soft Tissues Study Group (EpSSG). She is also a member of the scientific advisory committee of the International Society of Pediatric Oncology (SIOP) and, since 2020, a member of the SIOP Europe educational council.​

November 7 – 10.45 – 11.25am

Session:Keynote – Setting the Stage about the Importance of Pediatric Oncology Data Sharing​​

Role: Discussant

See others scientific committee members :

Serban NEGOITA

Serban NEGOITA

Serban NEGOITA

USA - National Cancer Institute

Dr. Serban Negoita, MD, DrPH, serves as Chief of the Data Quality, Analysis, and Interpretation Branch (DQAIB) with the Surveillance Research Program (SRP) of National Cancer Institute (NCI).

In this position, he works with SEER registries, NCI experts, and the cancer surveillance community to enhance the quality of cancer surveillance data. 

In addition, Dr Negoita’s research interests include descriptive statistics of clinical cancer outcomes, and more recently, the effect of COVID-19 pandemic on cancer statistics.

In 2021, Dr. Negoita has been appointed to the Executive Committee of the American Joint Committee on Cancer. In addition, he is the current SEER Program representative to the International Association of Cancer Registries.

Dr. Negoita earned his MD from the University of Medicine and Pharmacy in Bucharest, Romania and his DrPH from the State University of New York.

  • November 7 – 2.30pm – 5.15pm
  • November 8 – 10am – 12.30pm
  • November 8 (Wrap-up in panel session) –  2 – 3.30pm

Session: Workshop #1 Harmonization of Clinical & Biological Data  

Role: Facilitator

See others scientific committee members :

Jan F. NYGÅRD

Jan F. NYGÅRD

Jan F. NYGÅRD

Norway - Cancer Registry of Norway

Dr. Jan F Nygård earned his Cybernetics engineering degree from Oslo College of Engineering in 1991, minor in Political Science (1998) and a PhD in Epidemiology (2005) from the University of Oslo.

He began his career at the Institute of Community Medicine, University of Oslo (1992-1998) before joining the Cancer Registry of Norway in 1999. Since 2007, he has led the IT/Registry Informatics Department. 

His research focuses on the convergence of big data analytics, machine learning, data privacy, secure computing, and epidemiology. He has published 89 original research papers in peer-reviewed journals, and supervised MSc and PhD students from informatics and medical faculties. He also contributes to reference and steering committees.

In 2017, he was a visiting scientist at Lawrence Livermore National Laboratory, and as of July 1, 2021, he holds the position of Adjunct Associate Professor in the Machine Learning Group at UiT – The Artic University of Norway.

November 7 – 2.30 – 3.45pm

Session: Workshop #2 Interoperability – Session 1

Role: Discussant

See others scientific committee members :

Lynne PENBERTHY

Lynne PENBERTHY

Lynne PENBERTHY

USA - National Cancer Institute

Dr. Lynne Penberthy is the Associate Director for the Surveillance Research Program (SRP), which is within the Division of Cancer Control and Population Sciences (DCCPS) at the National Cancer Institute (NCI) since 2013. Dr. Penberthy obtained her MD from the University of Michigan and her MPH in epidemiology at Johns Hopkins.

Dr. Penberthy’s career includes a surgical internship in Baltimore, Maryland, at the Sinai Hospital and a preventive medicine residency at Johns Hopkins University. After her residency, she completed her post-doctoral training in epidemiology with the CDC as an epidemic intelligence service (EIS) officer with the Commonwealth of Virginia. She is licensed to practice medicine in the state of Maryland. Dr. Penberthy has a long history of focus on informatics and automation and has been involved in biobanking both in her academic role as well as at NCI.  

In addition to her role as SEER program director, she is the lead for the National Childhood Cancer Registry (NCCR) development and implementation under the Childhood Cancer Data Initiative (CCDI). The latter is a population based system based on cancer registries but brings in a multitude of other data sources to support research on childhood cancer.  

November 7 – 12.40 – 12.55pm

Session: Keynote – Introducing the international Childhood Cancer Data Partnership

Role: Discussant

See others scientific committee members :

Arnaud PETIT

Arnaud PETIT

France - Armand Trousseau Hospital

Professor Arnaud Petit, pediatric oncologist, head of the Pediatric Hematology and Oncology Department at Armand Trousseau Hospital (AP-HP).

He is part of the Hematopoietic and Leukemic Development research team (UMRS_938). He is chairman of the Leukemia Committee of SFCE (French Society against childhood cancers and leukemia) and co-chair of AML committee of the I-BFM Study group.

He is in charge of CONECT-AML (Consortium of French research teams involved in pediatric AML) and DOREMy project (French pediatric AML database).

 

November 8 – 10 – 11.15am

Session: Workshop #1 Harmonization of clinical and biological Data – Session 3

Role: Discussant

See others scientific committee members :

Bastien RANCE

Bastien RANCE

Bastien RANCE

France - Université Paris Cité​ AP-HP Paris Hospital​

Dr. Batien Rance is associate Professor of Medical Informatics at University of Paris Cité, School of Medicine and European Hospital Georges Pompidou, Assistance Publique – Hôpitaux de Paris.​

Specialties: Secondary use of healthcare data, health data warehouses, artificial intelligence in medicine, data integration for the life sciences, medical informatics, medical terminologies and ontologies.​

He is head of the data platform of the CARPEM research program (CAncer Research for PErsonalized Medicine) which brings together 350 researchers and physicians dedicated to cancer care and research. Their domain of competences covers Immunology, Genomics, Metabolism, Cellular Biology, Bioinformatics, Mathematics, Biostatistics, Medical Informatics, Microfluidics, Epidemiology and Ethics. ​

November 7 – 4pm – 5-15pm

Session: Workshop #1 Harmonization of Clinical & Biological Data – Session 2 

Role: Discussant

See others scientific committee members :

Paul RINAUDO

Paul RINAUDO

Paul RINAUDO

France - ADLIN-Science

Paul Rinaudo is entrepreneur and experienced Managing Director with a demonstrated history of working in the industrial And financial sector.
He is passionated about biology, teamwork and innovation.​
He is the Founder & CEO of ADLIN Science, a digital Healthtech which aims to accompany scientific researchers in the emergence of precision medecine, by developing tools enabling groundbreaking innovations in omic sciences and actively participate to the public research funding dilemna. ​

November 7 – 4pm – 5-15pm

Session: Workshop #2 Interoperability – Session 2

Role: Discussant

See others scientific committee members :

Paul SAULTIER

Paul SAULTIER

Paul SAULTIER

France - AP-HM, Inserm,  LEA platform

Dr Paul Saultier currently works as an associate professor at the Department of pediatric hematology, immunology and oncology, La Timone Children Hospital, APHM and at the C2VN, INSERM 1263, Aix Marseille University in Marseille, France. 

His main clinical and research interest is childhood leukemia survivorship. He is one of the coordinators of the LEA program. This program was implemented in 2004 in France and aims at promoting and studying long-term health in childhood survivors of leukemia. This program investigates the medical, genetic, socioeconomic, behavioral, and environmental determinants of long-term complications of survivors of childhood leukemia. 

November 8 – 10am – 11.15am

Session: Workshop #2 Interoperability

Role: Discussant

See others scientific committee members :

Gudrun SCHLEIERMACHER

Gudrun SCHLEIERMACHER

Gudrun SCHLEIERMACHER

France - Institut Curie

Physician-scientist originally from Heidelberg, Germany, Gudrun Schleiermacher is a pediatric oncologist and researcher at Institut Curie, Paris, France.

In addition to care for children and adolescents with cancer, she is involved in clinical and translational research programs. Her work focusses the study of molecular mechanisms involved in cancer progression and clonal evolution in neuroblastoma and other pediatric cancers, based on biomarker studies using liquid biopsies and on single cell analysis. Future aims are to integrate biomarkers into integrative treatment approaches, while working towards a better understanding of the underlying genetic and epigenetic modifications involved in the oncogenesis and tumor progression. She is also involved in personal and precision medicine approaches at a national and international level.

November 7 – 2.30 – 3.45pm

Session: Workshop #1 Harmonization of clinical and biological Data – Session 1

Role: Discussant

See others scientific committee members :

Click to listen highlighted text!